DANIEL ERNESTO
CASTELLANO GAUNA

Profesor asociado de Ciencias de la Salud

Foto de DANIEL ERNESTO

Foto de AstraZeneca (United Kingdom)

AstraZeneca (United Kingdom)

Cambridge, Reino Unido

Publications in collaboration with researchers from AstraZeneca (United Kingdom) (3)

2023

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53

2022

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405

2020

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588